

Clinical Policy: Factor VIII/von Willebrand Factor Complex (Human – Alphanate, Humate-P, Wilate); von Willebrand Factor (Recombinant – Vonvendi)

Reference Number: CP.PHAR.216

Effective Date: 05.01.16

Last Review Date: 02.23

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

The following are factor VIII/von Willebrand factor complexes (human) or recombinant von Willebrand factor requiring prior authorization: Alphanate[®], Humate[®]-P, Vonvendi[®], and Wilate[®].

FDA Approved Indication(s)

Factor VIII/von Willebrand factor complexes are indicated for:

- Hemophilia A
 - Alphanate: Control and prevention of bleeding episodes and perioperative management in adult and pediatric patients with factor VIII deficiency due to hemophilia A
 - Humate-P: Treatment and prevention of bleeding in adults with hemophilia A (classical hemophilia)
 - Wilate:
 - On-demand treatment and control of bleeding episodes
 - Routine prophylaxis to reduce the frequency of bleeding episodes
- Von Willebrand disease (VWD) in children and adults:
 - Alphanate: Surgical and/or invasive procedures in patients in whom desmopressin (DDAVP) is either ineffective or contraindicated
 - Humate-P:
 - Treatment of spontaneous and trauma-induced bleeding episodes
 - Prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD as well as patients with mild to moderate VWD where use of DDAVP is known or suspected to be inadequate
 - Wilate:
 - On-demand treatment and control of bleeding episodes
 - Perioperative management of bleeding

Vonvendi is indicated in adults with VWD for:

- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding
- Routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease receiving on-demand therapy

Limitation(s) of use: Alphanate is not indicated for patients with severe VWD (type 3) undergoing major surgery.

CLINICAL POLICY**Factor VIII/von Willebrand Factor Complex; von Willebrand Factor****Policy/Criteria**

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation® that Alphanate, Humate-P, Vonvendi, and Wilate are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Congenital Hemophilia A (must meet all):**

1. Diagnosis of congenital hemophilia A (factor VIII deficiency);
2. Request is for Alphanate, Humate-P, or Wilate;
3. Prescribed by or in consultation with a hematologist;
4. Request is for one of the following uses (a, b, or c):
 - a. Control or prevention of bleeding episodes;
 - b. Perioperative management (Alphanate only);
 - c. Routine prophylaxis to reduce the frequency of bleeding episodes (Wilate only);
5. For routine prophylaxis requests (Wilate only), for members who have not previously used Wilate for routine prophylaxis, member meets one of the following (a or b):
 - a. Member has severe hemophilia (defined as factor VIII level of < 1%);
 - b. Member has experienced at least one serious spontaneous bleed (*see Appendix D*);
6. If factor VIII coagulant activity levels are > 5%, failure of desmopressin acetate, unless contraindicated, clinically significant adverse effects are experienced, or an appropriate formulation of desmopressin acetate is unavailable;
7. Documentation of member's current body weight (in kg);
8. Dose does not exceed the FDA approved maximum recommended dose for the relevant indication.

Approval duration: 3 months (*12 months for prophylaxis for HIM Texas*)

B. Von Willebrand Disease (must meet all):

1. Diagnosis of one of the following (a or b):
 - a. VWD type 1 or 2 (except type 2B), and member has had a failure of desmopressin acetate, unless contraindicated, clinically significant adverse effects are experienced, or an appropriate formulation of desmopressin acetate is unavailable;
 - b. VWD type 2B or 3;
2. Prescribed by or in consultation with a hematologist;
3. For Vonvendi only: age \geq 18 years;
4. Request is for one of the following uses (a, b, or c):
 - a. Treatment of bleeding episodes (Humate-P, Vonvendi, and Wilate only);
 - b. Perioperative management;
 - c. Routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe VWD type 3 receiving on-demand therapy (Vonvendi only);
5. Documentation of member's current body weight (in kg);
6. Dose does not exceed the FDA approved maximum recommended dose for the relevant indication.

CLINICAL POLICY**Factor VIII/von Willebrand Factor Complex; von Willebrand Factor**

Approval duration: 3 months (*12 months for prophylaxis for HIM Texas*)

C. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy**A. All Indications in Section I** (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. Documentation of member's current body weight (in kg);
4. If request is for a dose increase, new dose does not exceed the FDA approved maximum recommended dose for the relevant indication.

Approval duration: 3 months (*12 months for prophylaxis for HIM Texas*)

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business:

CLINICAL POLICY

Factor VIII/von Willebrand Factor Complex; von Willebrand Factor

CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

DDAVP: desmopressin acetate

FDA: Food and Drug Administration

VWD: von Willebrand disease

vWF: von Willebrand factor

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
desmopressin acetate (Stimate [®] nasal spray; generic injection solution)	When Factor VIII coagulant activity levels are > 5% and for VWD type 1 or 2 (except 2B): Injection: 0.3 mcg/kg IV every 48 hours Nasal spray: < 50 kg: 1 spray intranasally in one nostril only; may repeat based on laboratory response and clinical condition ≥ 50 kg: 1 spray intranasally in each nostril; may repeat based on laboratory response and clinical condition	Injection: 0.3 mcg/kg IV every 48 hours Nasal spray: 1 spray intranasally in each nostril

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): factor VIII/vWF complex: patients with known hypersensitivity reactions, including anaphylactic or severe systemic reaction, to human plasma-derived

CLINICAL POLICY

Factor VIII/von Willebrand Factor Complex; von Willebrand Factor

products, any ingredient in the formulation, or components of the container; Vonvendi: history of life-threatening hypersensitivity reactions to Vonvendi or its components

- Boxed warning(s): none reported

Appendix D: General Information

- Serious bleeding episodes include bleeds in the following sites: intracranial, neck/throat, gastrointestinal, or joints (hemarthrosis).
- Spontaneous bleed is defined as a bleeding episode that occurs without apparent cause and is not the result of trauma.

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Factor VIII/von Willebrand factor complex (Alphanate)	Hemophilia A - control and prevention of bleeding episodes	Minor episodes: 15 IU/kg IV every 12 hours Moderate episodes: 25 IU/kg IV every 12 hours Major episodes: 40-50 IU/kg IV initially followed by 25 IU/kg IV every 12 hours	100 IU/kg/day
Factor VIII/von Willebrand factor complex (Humate-P)	Hemophilia A - control and prevention of bleeding episodes	Minor episodes: 15 IU/kg IV loading dose to achieve a FVIII:C plasma level of approximately 30% of normal; one infusion may be sufficient. If needed, half of the loading dose may be given once or twice daily Moderate episodes: 25 IU/kg IV loading dose to achieve a FVIII:C plasma level of approximately 50% of normal, followed by 15 IU/kg IV every 8-12 hours for the first 1-2 days to maintain the FVIII:C plasma level at 30% of normal. Continue the same dose once or twice daily for up to 7 days or until adequate wound healing is achieved. Major episodes: 40-50 IU/kg IV initially followed by 20-25 IU/kg IV every 8 hours to maintain the FVIII:C plasma level at 80-100% of normal for 7 days. Continue the same dose once or twice daily for another 7 days to maintain the FVIII:C level at 30-50% of normal.	75 IU/kg/day

CLINICAL POLICY

Factor VIII/von Willebrand Factor Complex; von Willebrand Factor

Drug Name	Indication	Dosing Regimen	Maximum Dose
Factor VIII/von Willebrand factor complex (Alphanate)	Hemophilia A – perioperative management	Pre-operative: 40-50 IU/kg IV once as a single dose Post-operative: 30-50 IU/kg IV every 12 hours	100 IU/kg/day
Factor VIII/von Willebrand factor complex (Humate-P)	VWD – control and prevention of bleeding episodes	<u>Type 1 VWD, mild disease</u> Minor or major episodes: 40-60 IU/kg IV loading dose followed by 40-50 IU/kg IV every 8-12 hours for 3 days to keep the trough level of VWF:RCo > 50%. Then 40-50 IU/kg daily for up to 7 days. <u>Type 1 VWD, moderate or severe disease</u> Minor episodes: 40-50 IU/kg IV as one or two doses Major episodes: 50-75 IU/kg loading dose followed by 40-60 IU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo > 50%. Then 40-60 IU/kg daily for up to 7 days. <u>Type 2 or 3 VWD</u> Minor episodes: 40-50 IU/kg IV as one or two doses Major episodes: 60-80 IU/kg IV loading dose followed by 40-60 IU/kg every 8-12 hours for 3 days to keep the trough level of VWF:RCo > 50%. Then 40-60 IU/kg daily for up to 7 days.	240 IU/kg/day
Factor VIII/von Willebrand factor complex (Wilate)	Hemophilia A - control and prevention of bleeding episodes	Minor or moderate episodes: 30-40 IU/kg IV every 12-24 hours Major episodes: 35-50 IU/kg IV every 12-24 hours Life-threatening episodes: 35-50 IU/kg IV every 8-24 hours	150 IU/kg/day
Factor VIII/von Willebrand	Hemophilia A – routine prophylaxis	20-40 IU/kg IV every 2 to 3 days	40 IU/kg/day

CLINICAL POLICY

Factor VIII/von Willebrand Factor Complex; von Willebrand Factor

Drug Name	Indication	Dosing Regimen	Maximum Dose
factor complex (Wilate)			
Factor VIII/von Willebrand factor complex (Wilate)	VWD – control and prevention of bleeding episodes	Minor episodes: 20-40 IU/kg IV loading dose followed by 20-30 IU/kg every 12-24 hours Major episodes: 40-60 IU/kg IV loading dose followed by 20-40 IU/kg every 12-24 hours	60 IU/kg/day
Factor VIII/von Willebrand factor complex (Wilate)	VWD – perioperative management	Minor surgeries (including tooth extraction): 30-60 IU/kg IV loading dose followed by 15-30 IU/kg every 12-24 hours Major surgeries: 40-60 IU/kg IV loading dose followed by 20-40 IU/kg every 12-24 hours	60 IU/kg/day
von Willebrand factor (Vonvendi)	VWD – treatment and control of bleeding episodes	Minor episodes: 40-50 IU/kg IV loading dose followed by 40-50 IU/kg every 8-24 hours Major episodes: 50-80 IU/kg IV loading dose followed by 40-60 IU/kg every 8-24 hours for approximately 2 to 3 days	Minor episodes: 150 IU/kg/day Major episodes: 180 IU/kg/day
von Willebrand factor (Vonvendi)	VWD – perioperative management	Minor surgeries: 25-30 IU/kg IV every 12-48 hours Major surgeries: 40-60 IU/kg IV every 12-48 hours	Minor surgeries: 60 IU/kg/day Major surgeries: 120 IU/kg/day
von Willebrand factor (Vonvendi)	VWD- Routine prophylaxis to reduce the frequency of	Initiation of prophylactic treatment: 40-60 IU/kg IV twice weekly	60 IU/kg twice weekly

CLINICAL POLICY

Factor VIII/von Willebrand Factor Complex; von Willebrand Factor

Drug Name	Indication	Dosing Regimen	Maximum Dose
	bleeding episodes in patients with severe type 3 VWD receiving on-demand therapy		

VI. Product Availability

Drug Name	Availability
Factor VIII/von Willebrand factor complex (Alphanate)	Vials: 250, 500, 1,000, 1,500 IU and 2,000 IU FVIII
Factor VIII/von Willebrand factor complex (Humate-P)	Vials: 250/600, 500/1,200, 1,000/2,400 IU FVIII/VWF:RCo
von Willebrand factor (Vonvendi)	Vials: 450-850 IU (5 mL), 900-1,700 IU (10 mL)
Factor VIII/von Willebrand factor complex (Wilate)	Vials: 500/500, 1,000/1,000 IU FVIII/VWF:RCo

VII. References

1. Alphanate Prescribing Information. Los Angeles, CA: Grifols Biologicals Inc.; June 2018. Available at <http://www.alphanate.com>. Accessed November 7, 2022.
2. Humate-P Prescribing Information. Kankakee, IL: CSL Behring, LLC; June 2020. Available at <http://www.humate-p.com>. Accessed November 7, 2022.
3. Vonvendi Prescribing Information. Lexington, MA: Baxalta US Inc.; January 2022. Available at: https://www.shirecontent.com/PI/PDFs/VONVENDI_USA_ENG.pdf. Accessed November 7, 2022.
4. Wilate Prescribing Information. Hoboken, NJ: Octapharma USA Inc.; March 2020. Available at <http://www.wilateusa.com>. Accessed November 7, 2022.
5. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. *Haemophilia*. 2020;26(suppl 6):1-158.
6. Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation (NHF): Database of treatment guidelines. Available at: <https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents>. Accessed November 7, 2022.
7. MASAC Document 266 - MASAC Recommendations Regarding the Treatment of von Willebrand Disease (Revised March 2021). Available at: <https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-266-masac-recommendations-regarding-the-treatment-of-von-willebrand-disease>. Accessed November 7, 2022.

CLINICAL POLICY

Factor VIII/von Willebrand Factor Complex; von Willebrand Factor

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J7183	Injection, von Willebrand factor complex (human), Wilate, 1 IU vWF:RCo
J7186	Injection, antihemophilic factor VIII/von Willebrand factor complex (human), per factor VIII i.u. (Alphanate)
J7187	Injection, von Willebrand factor complex (Humate-P), per IU VWF:RCO
J7179	Injection, von Willebrand factor (recombinant), (Vonvendi), per 1 IU vWF:rc0

Reviews, Revisions, and Approvals	Date	P&T Approval Date
1Q 2019 annual review: add HIM-Medical Benefit; no significant changes; references reviewed and updated.	09.26.18	02.19
1Q 2020 annual review: no significant changes; added HIM line of business; RT4 policy update addition of hemophilia A indication for Wilate, mirroring previously approved hemophilia A coverage policies for other FVIII products; references reviewed and updated.	11.27.19	02.20
Added Commercial line of business.	03.13.20	
Added 1 month approval duration for use post-valoctocogene gene therapy administration in hemophilia A for Wilate only.	04.17.20	05.20
Added Vonvendi to the policy; added routine prophylaxis-specific requirement for severe hemophilia classification or at least one life-threatening or serious spontaneous bleed for classification of non-severe hemophilia; added requirement for prescriber attestation of not partaking in contact sports.	05.27.20	08.20
Removed requirement for prescriber attestation of not partaking in contact sports.	10.01.20	11.20
1Q 2021 annual review: added requirement for documentation of member's body weight for calculation of appropriate dosage; removed references to valoctocogene, as it was not FDA-approved and likely will not face FDA review again until at least late 2022; for VWD type 1 or 2 (except 2B), added requirement for a prior trial of desmopressin; references to HIM.PHAR.21 revised to HIM.PA.154; references reviewed and updated.	12.01.20	02.21
Added a requirement for high utilizers of factor VIII products for routine prophylaxis to use Hemlibra.	09.20.21	11.21
1Q 2022 annual review: removed the redirection to Hemlibra for high factor utilizers until data analysis re: potential cost savings is complete; references reviewed and updated.	11.27.21	02.22

CLINICAL POLICY

Factor VIII/von Willebrand Factor Complex; von Willebrand Factor

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Clarified requirement for coverage of Wilate for routine prophylaxis: the requirement for factor VIII activity level or documentation of bleed history only applies to requests for new starts to routine prophylactic therapy; RT4: added newly approved indication for Vonvendi for routine prophylaxis.	03.15.22	05.22
Template changes applied to other diagnoses/indications.	10.05.22	
1Q 2023 annual review: Removed “life-threatening” from “life-threatening or serious bleed” criterion as definition of what is serious vs life-threatening may not be mutually exclusive and there exists potential for misinterpretation; references reviewed and updated.	11.07.22	02.23
Extended initial and continued authorization durations for hemophilia and von Willebrand disease prophylaxis from 3 months to 12 months for HIM Texas.	08.25.23	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

CLINICAL POLICY**Factor VIII/von Willebrand Factor Complex; von Willebrand Factor**

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.